- Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,
oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy.
- Measurable disease as defined per RECIST v. 1.1. Tumor lesions previously irradiated
or subjected to other locoregional therapy will only be deemed measureable if disease
progression at the treated site after completion of therapy is clearly documented.
- HPV- negative SCCHN tumor as determined per institutional standard (eg, p16 IHC;
multiplex nucleic acid sequence based amplification [NASBA] or other polymerase chain
reaction [PCR]-based assays).
- Documented progressive disease according to RECIST v1.1 (Appendix 2) following receipt
of at least 2 cycles of one platinum-containing chemotherapy regimen administered for
R/M disease (min. 50 mg/m2 for cisplatin, minimum area under the curve [AUC] > 4 for
- Availability of a tumor tissue specimen (ie, archived formalin fixed paraffin embedded
tissue [block preferred, or 15 unstained slides]), which will be used for centralized,
retrospective biomarker analysis. If archived tumor tissue is not available, then a de
novo biopsy will be required for patient participation.
- Prior nasopharyngeal cancer, salivary gland or sinus tumors.
- More than one chemotherapeutic regimen given for R/M disease. Prior treatment with
immunotherapy is allowed.
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases,
carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms,
cerebral edema, and/or progressive growth. Patients with a history of CNS metastases
or cord compression are eligible if they have been definitively treated with local
therapy (eg, radiotherapy, stereotactic surgery) and are clinically stable off
anticonvulsants and steroids for at least 4 weeks before randomization.
- Progressive disease within 3 months after completion of curatively intended treatment
for locoregionally advanced SCCHN.
- Difficulty swallowing capsules.
- Prior use of cetuximab in the R/M disease treatment setting (except cetuximab during